Sun Pharma withdraws 11 eye-drug brands in India after contamination concerns
Sun Pharma has asked distributors to halt sales of 11 ophthalmic products after eye specialists flagged possible Pseudomonas contamination. The company said 26 other eye medicines were not made at the affected facility and remain unaffected.
The brand move
Sun Pharma voluntarily withdrew Predmet and 11 ophthalmic products in India after eye specialists flagged possible Pseudomonas contamination. Distributors were asked to stop sales, while the company said 26 other eye medicines were not made at the affected facility.
The numbers
- 11 ophthalmic products withdrawn
- June 19 AIOS alert
- July 17 wider withdrawal
- August 1 letter
- 26 other ophthalmic products stated unaffected
Why it matters for the brand
Immediately quarantine the 11 recalled Sun Pharma eye-drug brands, secure substitute supply, and give pharmacists clear customer guidance to protect availability and trust.
What to track next
- Confirmation or rejection of Pseudomonas contamination in retained samples, market samples and patient-linked investigations.
- Any expansion from 11 brands to additional lots, dosage forms, plants or export-market products.
- Indian regulator inspection findings, formal recall notices, manufacturing restrictions or corrective-action requirements.
- Reported clusters of ocular infections, hospitalizations, visual impairment or other adverse events associated with implicated products.
- Length and breadth of distributor inventory holds, pharmacy stockouts and ophthalmology-clinic substitution patterns.
The counter-case
The signal may overstate the market impact: a distributor halt on 11 brands does not necessarily mean confirmed contamination, a regulator-mandated recall, broad patient exposure, or a lasting shortage. Sun Pharma says 26 other ophthalmic medicines were produced elsewhere and remain available, while competing generic suppliers may quickly cover any gaps. Without evidence of adverse events, confirmed Pseudomonas-positive batches, manufacturing shutdowns, or penalties, the commercial and reputational effects could be contained.